Search results for " bioplan"

Article The Future of Biopharma
TREND ANALYTICS To gain perspectives on these and other trends, BioPlan Associates asked the 425 global subject matter experts and senior participants on its Biotechnology Industry Council to eval…

Article The Challenge of Disruptive Technologies in Bioprocessing
The Challenge of Disruptive Technologies in BioprocessingIncreasing demand for biologics is driving the need for innovation in bioprocessing. Jul 01, 2018 Increasing demand for biologics is drivin…

Article Tools and Processes for Mature and Emerging Therapies
While the approvals of cell therapies and gene therapies has been exciting, turning clinical processes into operational processes will prove challenging, said Eric Langer, managing partner, BioPlan As…

Article Biomanufacturing: The Cost of Unskilled Workers
First, a 2018 report from BioPlan Associates estimates there are well over 10,000 therapeutics in R&D, both drugs (chemical substance pharmaceuticals) and biopharmaceuticals (biotechnology-derived pha…

Article Advancing Single-Use Technology Through Collaboration
By working together to harmonize the highly variable steps within the biopharmaceutical manufacturing process, both end users and suppliers are making strides toward the efficiency and integrity of …

Article A Q&A with Eric Langer: CMOs Embrace New Technology
Process Development Forum speaks with Eric Langer, President and Managing Partner at BioPlan Associates, and the author of a number of biopharma studies, about the 2016 13th Annual Report and Survey…

Article Q&A with Eric Langer, about the evolution of the role of CMO’s in Bioprocessing
This week Process Development Forum speaks with Eric Langer, President and Managing Partner at BioPlan Associates, and the author of a number of biopharma studies, about the role of CMO’s in Bioproc…

Previous Page